We are currently experiencing technical issues due to the Microsoft outage. This will affect delivery of multi-factor authentication emails, invoice emails and service emails. We apologise for the disruption.

Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesVentyx Biosciences Inc

Ventyx Biosciences Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
None USD 0.00(0%)
Last update at 2026-04-09T21:02:34.405244Z
Market Cap
361.66M

Momentum Score

…

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
1.86
Low
40.58
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
-
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.05
ROE
-56.76%
Net Debt
-39.07M
ROCE
-44.29%
Diluted EPS TTM
-3.80

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -108.43M -83.75M -28.17M -4.33M
Net income -107.96M -78.37M -28.53M -4.47M
Selling general administrative 25.40M 8.67M 0.68M 0.63M
Reconciled depreciation 0.47M 0.03M 0.00M 0.00M
Ebit -113.14M -67.15M -7.05M -4.18M
Ebitda -108.43M -72.60M -7.05M -4.18M
Depreciation and amortization 4.71M -5.45M -0.00M -0.00M
Non operating income net other 4.71M -16.50M - -
Operating income -113.14M -67.15M -7.05M -4.18M
Other operating expenses 113.14M 67.15M 7.05M 4.18M
Interest expense 4.71M 0.10M 0.36M 0.15M
Interest income 4.67M - - -
Net interest income 4.67M -0.10M -0.36M -0.15M
Income tax expense -0.47M -5.38M 0.36M 0.15M
Total revenue 0.00M 0.00M 0.00M 0.00M
Total operating expenses 113.14M 67.15M 7.05M 4.18M
Total other income expense net 4.71M -16.60M -21.12M -0.15M
Net income from continuing ops -108.43M -83.75M -28.17M -4.33M
Net income applicable to common shares -108.43M -85.30M -28.17M -4.33M
Preferred stock and other adjustments - 1.55M - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 277.69M 371.40M 291.48M 0.24M 0.35M
Other current assets 12.12M 12.75M 4.44M 0.00M 0.04M
Total liab 33.77M 17.50M 12.28M 30.90M 4.48M
Total stockholder equity 243.92M -226.22M -117.80M -30.65M -4.13M
Other current liab 15.51M 9.51M 7.62M 0.30M 0.27M
Common stock 0.01M 0.01M 0.01M - -
Capital stock 0.01M 0.01M 0.01M 0.00M 0.00M
Retained earnings -419.19M -226.22M -117.80M -32.50M -4.33M
Other liab - - - 16.85M -
Other assets 0.00M 0.10M 0.06M - -
Cash 51.58M 64.82M 70.79M 0.24M 0.31M
Total current liabilities 22.27M 16.36M 12.28M 1.40M 0.63M
Net debt -39.07M -63.26M -70.79M 12.40M 3.54M
Short term debt 1.00M 0.41M - - -
Short long term debt total 12.51M 1.56M - 12.65M 3.85M
Other stockholder equity 663.15M 1.12M 0.05M 1.85M 0.20M
Property plant equipment - 0.41M 0.25M - -
Total current assets 264.35M 330.69M 263.02M 0.24M 0.35M
Long term investments 0.00M 38.67M 28.15M - -
Net tangible assets - 353.89M -87.62M -30.65M -4.13M
Short term investments 200.64M 253.12M 187.78M - -
Net receivables 0.80M 0.10M 0.06M - -
Long term debt - - - 12.65M 3.85M
Inventory -0.80M - - - -
Accounts payable 5.76M 6.43M 4.66M 1.10M 0.36M
Accumulated other comprehensive income -0.05M -1.12M -0.06M - -
Common stock total equity - 0.01M 0.01M - -
Retained earnings total equity - -226.22M -117.80M - -
Non currrent assets other 1.08M 0.10M 0.06M - -
Non current assets total 13.35M 40.71M 28.46M 0.00M 0.00M
Capital lease obligations 12.51M 1.56M - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments -74.66M -216.00M -216.00M -216.00M
Change to liabilities 3.50M 2.44M 0.59M 0.36M
Total cashflows from investing activities -74.93M -214.37M -214.37M -214.37M
Net borrowings - 0.45M 6.13M 2.95M
Total cash from financing activities 167.77M 323.55M 6.13M 2.95M
Change to operating activities -6.77M 1.57M 0.22M 0.23M
Net income -108.43M -83.75M -28.17M -4.33M
Change in cash -5.97M 70.55M -0.07M 0.31M
Begin period cash flow 70.79M 0.24M 0.31M 0.00M
End period cash flow 64.82M 70.79M 0.24M 0.31M
Total cash from operating activities -98.77M -38.65M -6.20M -2.64M
Issuance of capital stock 165.40M 323.04M 0.00M 0.00M
Depreciation 0.47M 0.03M 0.03M 0.03M
Other cashflows from investing activities - 1.90M - -
Sale purchase of stock 0.27M 323.10M - -
Other cashflows from financing activities 2.11M 164.74M 6.13M 2.95M
Change to netincome 16.57M 41.05M 21.17M 1.09M
Capital expenditures 0.28M 0.26M 0.26M 0.26M
Cash flows other operating -10.54M 12.24M - -
Exchange rate changes - 0.01M - -
Cash and cash equivalents changes -5.93M 70.55M - -
Change in working capital -5.16M 4.02M 0.81M 0.59M
Stock based compensation 16.57M 2.73M 0.04M 0.20M
Other non cash items -2.23M 38.32M 21.12M 0.90M
Free cash flow -99.05M -38.91M -6.20M -2.64M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
NVO
Novo Nordisk A/S		 -0.54
1.32%		 40.55 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc		 -2.37
0.43%		 544.66 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc		 -2.77
0.29%		 956.64 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 36.06

Profile*

Ventyx Biosciences Inc

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.

12790 El Camino Real, San Diego, CA, United States, 92130

760 593 4832

https://ventyxbio.com

74

Name Title Year Born
Dr. Sheila K. Gujrathi M.D. Exec. Chair 1970
Dr. Raju S. Mohan Ph.D. Founder, CEO & Director 1958
Dr. John M. Nuss Ph.D. Chief Scientific Officer 1959
Mr. Christopher W. Krueger J.D., MBA Chief Bus. Officer 1968
Prof. William J. Sandborn M.D., Ph.D. Pres & Chief Medical Officer NA
Dr. Martin Douglas Auster M.D. Chief Financial Officer 1975
Dr. Sheila K. Gujrathi M.D. Executive Chairperson 1970
Dr. Raju S. Mohan Ph.D. Founder, CEO, President & Director 1958
Mr. Christopher W. Krueger J.D., MBA Chief Business Officer 1968

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CJT
CAD 111.15
+12.71%
CLS
CAD 374.20
+8.33%
GRZ
CAD 4.90
+7.46%
CTC-A
CAD 218.05
+6.38%
FEC
CAD 7.42
+5.85%
TF
CAD 4.13
-19.65%
TLO
CAD 5.98
-15.06%
FSZ
CAD 2.45
-14.04%
XNDU
CAD 3.60
-8.86%
ITR
CAD 2.75
-8.50%

Equity Sectors*

  • Basic Materials

    -2.63%

  • Communication Services

    -0.79%

  • Consumer Cyclical

    +0.08%

  • Consumer Defensive

    -0.12%

  • Energy

    +0.52%

  • Financial Services

    -1.15%

  • Healthcare

    -1.74%

  • Industrials

    -0.64%

  • Real Estate

    -0.12%

  • Technology

    -0.51%

  • Utilities

    -0.02%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…